AGIO vs ARGX Stock Comparison
ARGX currently leads AGIO in this stock comparison, with AIQ scores of 74 vs 56. The clearest difference is risk resilience.
What is the main difference between AGIO and ARGX?
ARGX leads the current stock comparison as argenx SE, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Agios Pharmaceuticals, Inc. vs argenx SE
ARGX leads
ARGX leads by 18 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 21 points over 30 sessions.
Stable: 5 of 6 evidence groups support ARGX, its lead is narrowing, and its current signal state is conflicted.
Agios Pharmaceuticals, Inc.
argenx SE
The Algovestiq AIQ Score currently favors ARGX over AGIO, 74 versus 56 as of Nov 15, 2026. ARGX's advantage is driven primarily by stronger risk resilience and quality. ARGX also shows the stronger technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor ARGX today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. ARGX lead: Weakening — the AIQ differential moved from 21 to 18 points over 30 sessions. ARGX leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare Agios Pharmaceuticals, Inc. and argenx SE across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare AGIO and ARGX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience47 vs 70ARGX +23
- Quality58 vs 77ARGX +19
- Value52 vs 70ARGX +18
- Momentum61 vs 74ARGX +13
5 of 6 evidence groups favor ARGX. ARGX’s edge is concentrated in risk resilience and quality.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.30x)
Largest factor move: Momentum -4
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.55x)
- RSI Bearish Divergence — bearish, momentum, medium horizon
ARGX's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — AGIO and ARGX both carry a full feed there.
The central trade-off
ARGX (argenx SE): the stronger current systematic profile, led by risk resilience and quality.
AGIO (Agios Pharmaceuticals, Inc.): the counter-case, on fundamentals — but at materially higher volatility, 96.3% against 36.7%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ARGXARGX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
AGIOAGIO on combined revenue and EPS growth.
Value
ARGXARGX on the peer-relative Value factor, by 18 points.
Momentum
ARGXARGX on the Momentum factor, by 13 points.
Lower downside
ARGXARGX on Risk Resilience, by 23 points.
Analyst upside
ARGXARGX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | AGIO | ARGX | Note |
|---|---|---|---|
| Implied upside to target | +10.8% | +21.7% | ARGX has more room |
| Target dispersion | 0% | +46.1% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 10 | 24 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor ARGX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ARGX | 56 vs 74 |
| Fundamentals | AGIOon balance | revenue growth 23.8% vs -38.9%; EPS growth 35.5% vs -40.2%; gross margin 91.9% vs 90.5%; operating margin -297.7% vs 29.3% — AGIO takes 3 of 4 decided legs, not all of them |
| Valuation | ARGX | Value 52 vs 70 |
| Technicals | ARGX | Price vs 50-day -4.5% vs 3.9%; vs 200-day -0.8% vs 11.6% |
| Risk Resilience | ARGX | Risk Resilience 47 vs 70 |
| Analyst expectations | ARGX | Target upside 10.8% vs 21.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AGIO and ARGX and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 18 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ARGX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ARGX lead: Weakening — the AIQ differential moved from 21 to 18 points over 30 sessions.
- Today
- ARGX +18
- 56 vs 74
- 7 sessions ago
- ARGX +17
- 57 vs 74
- 30 sessions ago
- ARGX +21
- 49 vs 70
- 90 sessions ago
- ARGX +13
- 58 vs 71
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish / 2 neutral, conflicted
Only AGIO
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.84%)
- Beta Spike Warning — bearish, risk_regime, long horizon
4 bullish / 2 bearish / 1 neutral, conflicted
Only ARGX
- ADX Trend Strengthening — neutral, trend, medium horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- RSI Bearish Divergence — bearish, momentum, medium horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, Low Volume Rally Warning.
ARGX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.54%, AIQ 0 points).
Price and the AIQ Score both moved down over the latest session (price -2.17%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1AGIO closes the Risk Resilience gap — currently 23 points behind, the largest single contributor to ARGX's edge.
- 2AGIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3ARGX's conflicting signal state resolves bearish — it currently carries 4 bullish and 2 bearish rules at once.
- 4The narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 18-point move would eliminate ARGX's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
AGIO leads on balance| Metric | AGIO | ARGX |
|---|---|---|
| Revenue growth (YoY) | 23.8% | -38.9% |
| EPS growth (YoY) | 35.5% | -40.2% |
| Gross margin | 91.9% | 90.5% |
| Operating margin | -297.7% | 29.3% |
| Return on equity (TTM) | -6.6% | 0% |
| Debt to equity | 0.03 | 0.01 |
Performance
ARGX leads 4 of 6 windows| Metric | AGIO | ARGX |
|---|---|---|
| 1 week (5 sessions) | 7.4% | 3.5% |
| 1 month (20 sessions) | 0.9% | 17.2% |
| 3 months (63 sessions) | -6.1% | -2.8% |
| 6 months (126 sessions) | 12.1% | 20.1% |
| Year to date | 16.1% | 14.2% |
| 1 year (252 sessions) | -27.6% | 7.9% |
Technicals
ARGX has the stronger structure| Metric | AGIO | ARGX |
|---|---|---|
| RSI (14) | 46.3 | 58.8 |
| ADX (14) | 20.6 | 21 |
| Price vs 50-day | -4.5% | 3.9% |
| Price vs 200-day | -0.8% | 11.6% |
| Volatility (1M, annualized) | 96.3% | 36.7% |
Risk
ARGX is the more resilient| Metric | AGIO | ARGX |
|---|---|---|
| Beta | 0.93 | 0.53 |
| Sharpe ratio | 0.07 | 0.28 |
| Sortino ratio | 0.08 | 0.43 |
| Max drawdown | -50.9% | -28.6% |
| Current drawdown | -30.6% | -9.3% |
| Annualized volatility | 80% | 37.9% |
| Value at risk (95%) | -3.9% | -3.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AGIO or ARGX?
On the Algovestiq AIQ Score, ARGX is the stronger of the two as of Nov 15, 2026, scoring 74 against AGIO's 56. The edge comes from risk resilience and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AGIO or ARGX the better buy right now?
ARGX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor ARGX over AGIO?
The composite weights Quality, Value, Momentum and Risk Resilience. ARGX leads Risk Resilience by 23 points; ARGX leads Quality by 19 points; ARGX leads Value by 18 points. ARGX leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by AGIO simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, AGIO or ARGX?
Analyst price targets imply +10.8% upside for AGIO and +21.7% for ARGX, so the Street currently favors ARGX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AGIO or ARGX?
ARGX is the better-valued of the two on the peer-relative Value factor. ARGX on the peer-relative Value factor, by 18 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AGIO or ARGX?
AGIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AGIO or ARGX?
ARGX on the Momentum factor, by 13 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AGIO or ARGX?
ARGX is the more resilient of the two, so the other name carries the higher downside risk. ARGX on Risk Resilience, by 23 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AGIO more profitable than ARGX?
The profitability evidence is mixed: gross margin 91.9% vs 90.5%; operating margin -297.7% vs 29.3%; ttm roe -6.6% vs 0%. Each name leads on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is ARGX's lead over AGIO getting stronger or weaker?
ARGX lead: Weakening — the AIQ differential moved from 21 to 18 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the AGIO vs ARGX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AGIO closes the Risk Resilience gap — currently 23 points behind, the largest single contributor to ARGX's edge; AGIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ARGX's conflicting signal state resolves bearish — it currently carries 4 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 18-point move would eliminate ARGX's advantage entirely.
What do the current signals say about AGIO and ARGX?
AGIO: 1 bullish / 2 bearish / 2 neutral, conflicted. ARGX: 4 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AGIO is Golden Cross Active (bullish, long horizon). On ARGX it is Golden Cross Active (bullish, long horizon).
Compare AGIO and ARGX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.